Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
15K
-
Shares change
-
+14.8K
-
Total reported value, excl. options
-
$22.1K
-
Value change
-
+$21.8K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$1.47
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q4 2023
2 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15K shares
of 55.7M outstanding shares and own 0.03% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (4.3M shares), VANGUARD GROUP INC (1.64M shares), ADAR1 Capital Management, LLC (1.07M shares), Atlas Venture Life Science Advisors, LLC (1.01M shares), Alphabet Inc. (890K shares), Murchinson Ltd. (863K shares), RENAISSANCE TECHNOLOGIES LLC (547K shares), BlackRock Inc. (481K shares), GEODE CAPITAL MANAGEMENT, LLC (413K shares), and AMERIPRISE FINANCIAL INC (403K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.